2. 您的位置
3. 首页
4. 会议论文
5. TransCelerate Overview

TransCelerate Overview

来源 :亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018) | 被引量 : 0次 | 上传用户：lillian0606

【摘 要】

：

Currently, 19 of the Worlds Most Successful Biopharmaceutical Companies Comprise TransCelerate Membership TransCelerate is a Nonprofit Entity Created in 2012 to Drive Collaboration

【作 者】

：

QingAn Jiao 

【机 构】

：

TransCelerate BioPharma Inc

【出 处】

：

亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018)

【发表日期】

：

2018年4期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Currently, 19 of the Worlds Most Successful Biopharmaceutical Companies Comprise TransCelerate Membership TransCelerate is a Nonprofit Entity Created in 2012 to Drive Collaboration

其他文献

Population pharmacokinetic pharmacodynamics model for PEGylated human growth hormone in healthy subj

Background: Growth hormone deficiency (GHD) in paediatric and adult patients so currently necessitates long-term treatment and persistence with a daily s.c injection regimen.Taking the low compliance

会议

Pharmacokinetic/Pharmacodynamic Modeling: Effect of Ibutilide on the QTcF Interval in Healthy Male S

Background: Ibutilide, a class Ⅲ antiarrhythmic agent, is primarily used for conversion of atrial flutter and fibrillation and is a good alternative to electrical cardioversion.However, ibutilide incr

会议

pharmacokineticibutilideEmax model

Selecting the target dose for phase Ⅱ clinical test of new drug using population approach of pre-cli

Introduction and purpose: Influenza viruses can show resistance to anti-viral drugs.This can result from over-use of these drugs and also due to the ability of influenza virus to mutate rapidly.For th

会议

Influenza virusphase Ⅱ clinical trialNONMEMsimulationWinNolin

Application of Physiologically Based Pharmacokinetic Modeling in Apatinib Clinical Pharmacokinetic S

Outlines · Introduction · In vitro ADME Properties · PBPK Modeling · Clinical PK of Apatinib in Healthy Volunteers · Prediction of Food Effect on Apatinib PK and DDIs using PBPK Model Introduction · A

会议

The effect of poor compliance on the pharmacokinetics of valproic acid in children with epilepsy usi

Objective: To investigate the effects of delayed and missed doses(poor compliance) on the pharmacokinetics of valproic acid(VPA) in epileptic children using Monte Carlo simulation.Methods: VPA time-co

会议

Predictions about probabilities of adverse events and appropriate dose of roflumilast for Chinese CO

Backgrounds: Roflumilast is an oral inhibitor of phosphodiesterase 4(PDE4), which is mainly metabolized by CYP3A4 and CYP1A2.The main metabolite of it is roflumilast N-oxide, which contributes to the

会议

Optimizing dosage regimens of piperacillin/tazobactam based on population pharmacokinetic and pharma

Background Piperacillin/tazobactam is an extended-spectrum β-lactamase inhibitor combination antibiotic and is commonly recommended as a first-line therapy for severe bacterial infections.As a time-de

会议

Effect of Target-Mediated Drug Disposition on CPRC3 Pharmacokinetics and Pharmacodynamics in Healthy

Background: The prevalence of diabetes mellitus (DM) dramatically increased over the past decades.Dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a relatively new group of anti-diabetic agents.CPRC3 is

会议

DPP-4 inhibitorCPRC3pharmacokineticstarget-mediated drug disposition model

Combining “Bottom-up” and “Top-down” methods to assess ethnic difference in clearance of bitopertin

Outline ·Background and Objectives · Methods ·Results ·Discussion ·Conclusions Background-Bitopertin ·Bitopertin is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunctio

会议

Development Strategies of Anti-PD-1 mAb for Tumor Therapeutics in China for Global Market

Lower-incidence tumor types are expected to account for ＞50％ of sales by 2020Product life cycle has shortened by almost fivefold from HER2 to now

会议